Gary Stephens investigates how neuroactive agents modulate synaptic function using electrophysiology, calcium imaging, and cell and animal disease models. Work spans ion‑channel pharmacology, seizure and pain mechanisms, and biopharmaceutics. He contributes to reporting guidance and holds IP in phytocannabinoid‑based compositions.